These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2569803)

  • 21. [Drug compliance and health locus of control in schizophrenia].
    Combes C; Feral F
    Encephale; 2011 May; 37 Suppl 1():S11-8. PubMed ID: 21600328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First person account: talking through medication issues: one family's experience.
    Mann SB
    Schizophr Bull; 1999; 25(2):407-9. PubMed ID: 10416741
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical symptomatology and drug compliance in schizophrenic patients.
    Bartkó G; Herczeg I; Zádor G
    Acta Psychiatr Scand; 1988 Jan; 77(1):74-6. PubMed ID: 2894746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years.
    Linden M; Godemann F; Gaebel W; Köpke W; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
    Schizophr Bull; 2001; 27(4):585-96. PubMed ID: 11824485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
    Knudsen P
    Acta Psychiatr Scand Suppl; 1985; 322():51-75. PubMed ID: 2866666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depressive syndromes in schizophrenic patients after discharge from hospital. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich.
    Bandelow B; Müller P; Gaebel W; Köpcke W; Linden M; Müller-Spahn F; Pietzcker A; Reischies FM; Tegeler J
    Eur Arch Psychiatry Clin Neurosci; 1990; 240(2):113-20. PubMed ID: 1981149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The psychological consequences of tardive dyskinesia. The effect of drug-induced parkinsonism and the topography of the dyskinetic movements.
    Brown KW; White T
    Br J Psychiatry; 1991 Sep; 159():399-403. PubMed ID: 1683594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tardive dyskinesia and type II schizophrenia.
    Davis EJ; Borde M; Sharma LN
    Br J Psychiatry; 1992 Feb; 160():253-6. PubMed ID: 1347240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Revealed" Depression and drug treatment for schizophrenia.
    Knights A; Hirsch SR
    Arch Gen Psychiatry; 1981 Jul; 38(7):806-11. PubMed ID: 6113822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term depot antipsychotics. A risk-benefit assessment.
    Barnes TR; Curson DA
    Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
    Singh H; Hunt JI; Vitiello B; Simpson GM
    J Clin Psychiatry; 1990 Aug; 51(8):319-21. PubMed ID: 1974249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
    Soni SD; Sampath G; Shah A; Krska J
    Acta Psychiatr Scand; 1992 May; 85(5):354-9. PubMed ID: 1351333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression.
    Curson DA; Barnes TR; Bamber RW; Platt SD; Hirsch SR; Duffy JC
    Br J Psychiatry; 1985 May; 146():469-74. PubMed ID: 3893599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The lifetime outcome and involuntary movements of schizophrenia never treated with neuroleptic drugs. Four rare cases in Ireland.
    Waddington JL; Youssef HA
    Br J Psychiatry; 1990 Jan; 156():106-8. PubMed ID: 1967543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of negative symptoms with tardive dyskinesia in schizophrenic patients.
    Chiu H; Lau J; Lam L; Shum P
    Aust N Z J Psychiatry; 1993 Jun; 27(2):228-32. PubMed ID: 8103320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight.
    Garavan J; Browne S; Gervin M; Lane A; Larkin C; O'Callaghan E
    Compr Psychiatry; 1998; 39(4):215-9. PubMed ID: 9675506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP].
    Buis C; Gourion D; Vaiva G
    Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.